CD4 and myeloid sarcoma: There were no major differences in the distribution of AIM+CD4 T cells among these memory T cell subsets between patients with MS treated with aCD20 and healthy controls, with most AIM+CD4 T cells mapping to the TCM and TEM1 subsets (Fig. 3d) in both groups.